Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Study of Pevonedistat in Combination With Select Standard of Care Agents in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myelogenous Leukemia, or Advanced Solid Tumors With Severe Renal Impairment or Mild or Moderate Hepatic Impairment

Next Previous
Trial Profile

A Phase 1/1b Study of Pevonedistat in Combination With Select Standard of Care Agents in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myelogenous Leukemia, or Advanced Solid Tumors With Severe Renal Impairment or Mild or Moderate Hepatic Impairment

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pevonedistat (Primary) ; Azacitidine; Azacitidine; Carboplatin; Docetaxel; Paclitaxel
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Leukaemia; Myelodysplastic syndromes; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Takeda; Takeda Oncology

Most Recent Events

  • 08 Jun 2022 Status changed from active, no longer recruiting to completed.
  • 07 Feb 2022 Planned End Date changed from 14 Jan 2022 to 31 May 2022.
  • 27 Oct 2021 Planned End Date changed from 6 Apr 2021 to 14 Jan 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top